/PRNewswire/ UCB, a global biopharmaceutical company, today announced that Annals of the Rheumatic Diseases has published 24-week results from the Phase 3.
Top-line results show that the two Phase 3 studies, BE HEARD I and BE HEARD II, met their primary and key secondary endpoints with statistical significance and.
Two articles report results from the Phase 3 BE OPTIMAL and BE COMPLETE studies evaluating bimekizumab, a selective inhibitor of IL-17A and IL-17F, in patients with psoriatic arthritisBrussels (Belgium), 7th December 2022 – 07:00 (CET) – UCB, a global biopharmaceutical company, today announced that .
Vitamin C Boosts Health In 11 Powerful Ways drleonardcoldwell.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from drleonardcoldwell.com Daily Mail and Mail on Sunday newspapers.